Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | SPR | P35270 | 1/20 | 0.35 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25273247 | 0.80 | SMN1; SMN2 (0.53) | ALDH1A1KDM4EGAATHRB | |
| SCHEMBL25278094 | 0.80 | SMN1; SMN2 (0.53) | ALDH1A1KDM4EGAATHRB | |
| SCHEMBL25735170 | 0.79 | KEAP1 (0.42) | MEN1KMT2AALDH1A1 | |
| SCHEMBL25273766 | 0.77 | AKR1C3 (0.39) | CHRM1CHRM2CHRM3AKR1C3SPR | |
| SCHEMBL25277651 | 0.77 | CHRNB2 (0.48) | MEN1KMT2AALDH1A1CHRM1CHRM2 | |
| SCHEMBL25236879 | 0.77 | HDAC3 (0.55) | CHRM1CHRM2CHRM3CYP2C9 | |
| SCHEMBL25273235 | 0.77 | HDAC3 (0.55) | CHRM1CHRM2CHRM3CYP2C9 | |
| SCHEMBL25259072 | 0.77 | HDAC3 (0.55) | CHRM1CHRM2CHRM3CYP2C9 | |
| SCHEMBL25215735 | 0.76 | HRH2 (0.41) | ALDH1A1KDM4E | |
| SCHEMBL13738562 | 0.75 | HDAC3 (0.56) | CHRM1CHRM2CHRM3CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067607-A1 | Pyridinylcyanoguanidine Derivative and Use Thereof | WANG, ZHEMING (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240067607-A1 | Pyridinylcyanoguanidine Derivative and Use Thereof | WANG, ZHEMING (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240067607-A1 | Pyridinylcyanoguanidine Derivative and Use Thereof | WANG, ZHEMING (CN) | 2024-02-29 | — | — | US | disclosed |
| US-11873284-B2 | Pyridinylcyanoguanidine derivative and use thereof | WANG, Zheming (CN) | 2024-01-16 | — | — | US | disclosed |
| US-11873284-B2 | Pyridinylcyanoguanidine derivative and use thereof | WANG, Zheming (CN) | 2024-01-16 | — | — | US | disclosed |
| US-11873284-B2 | Pyridinylcyanoguanidine derivative and use thereof | WANG, Zheming (CN) | 2024-01-16 | — | — | US | disclosed |
| US-20230192615-A1 | Pyridinylcyanoguanidine Derivative and Use Thereof | Rushi Biotech (Hangzhou) Co., Ltd (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192615-A1 | Pyridinylcyanoguanidine Derivative and Use Thereof | Rushi Biotech (Hangzhou) Co., Ltd (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192615-A1 | Pyridinylcyanoguanidine Derivative and Use Thereof | Rushi Biotech (Hangzhou) Co., Ltd (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192651-A1 | Pyrrolidine Derivative and Use Thereof | WANG, ZHEMING (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192651-A1 | Pyrrolidine Derivative and Use Thereof | WANG, ZHEMING (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192651-A1 | Pyrrolidine Derivative and Use Thereof | WANG, ZHEMING (CN) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067607-A1 | Pyridinylcyanoguanidine Derivative and Use Thereof | NAMPT, NAPRT, NNMT | MEN1 3461/4885KMT2A 467/4885ALDH1A1 1993/4885 |
| US-11873284-B2 | Pyridinylcyanoguanidine derivative and use thereof | NAMPT, NAPRT, NNT | MEN1 3478/4885KMT2A 506/4885ALDH1A1 1855/4885 |
| US-20230192651-A1 | Pyrrolidine Derivative and Use Thereof | NAMPT, NAPRT, NNMT | MEN1 3039/4885KMT2A 1430/4885ALDH1A1 1525/4885 |
| US-20230192615-A1 | Pyridinylcyanoguanidine Derivative and Use Thereof | NAMPT, NAPRT, NNT | MEN1 3478/4885KMT2A 506/4885ALDH1A1 1855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.